Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 26 Oct 2021
Large employer group launches pharmacy benefit management business
26 October 2021 - A non-profit coalition of nearly 40 companies, including U.S. retailers Walmart and Costco, said on Monday it ...
Posted by Michael Wonder on 26 Oct 2021
Cystic fibrosis medicine added to PHARMAC's options for investment list
27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has ...
Posted by Michael Wonder on 26 Oct 2021
Lilly pipeline success strengthens future growth potential
27 October 2021 - Lilly announces today its U.S. submission of tirzepatide in type 2 diabetes using a priority review ...
Posted by Michael Wonder on 26 Oct 2021
MHRA licenses Ryeqo for symptoms of uterine fibroids
26 October 2021 - The Medicines and Healthcare products Regulatory Agency has licensed Gedeon Richter UK’s Ryeqo (relugolix combination therapy) ...
Posted by Michael Wonder on 26 Oct 2021
Geron enters new innovative licensing and access pathway in the United Kingdom for imetelstat
25 October 2021 - Innovation Passport Designation Awarded to Imetelstat for the Treatment of Lower Risk Myelodysplastic Syndromes. ...
Posted by Michael Wonder on 26 Oct 2021
Theratechnologies announces reimbursement agreement in Italy for Trogarzo for eligible patients with multi-drug resistant HIV-1
26 October 2021 - Theratechnologies is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, ...
Posted by Michael Wonder on 26 Oct 2021
Eyenovia announces reclassification of MydCombi as drug device combination product by FDA
25 October 2021 - Company received complete response letter with additional requests and is preparing necessary documents for expedited resubmission, ...
Posted by Michael Wonder on 26 Oct 2021
Bausch + Lomb and Clearside Biomedical announce FDA approval of Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular oedema Associated with Uveitis
25 October 2021 - Xipere is the first and only medicine to be approved in the United States for delivery ...
Posted by Michael Wonder on 26 Oct 2021
NICE draft guidance does not recommend tucatinib for advanced breast cancer
26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in ...
Posted by Michael Wonder on 26 Oct 2021
Generating high quality evidence from registry based studies
26 October 2021 - EMA has published guidance to provide key methods and good regulatory practices to pharmaceutical organisations on ...
Posted by Michael Wonder on 26 Oct 2021
The challenges of inadequate financial support for Australians with cancer
21 October 2021 - The publicly funded Medicare system in Australia has been recognised as a leading universal health care model. ...
Posted by Michael Wonder on 25 Oct 2021
Spikevax: EMA recommendation on booster
25 October 2021 - The EMA’s CHMP has concluded that a booster dose of the COVID-19 vaccine Spikevax (from Moderna) ...
Posted by Michael Wonder on 25 Oct 2021
Merck and Ridgeback announce initiation of a rolling review by the European Medicines Agency for molnupiravir, an investigational oral anti-viral medicine, for the treatment of COVID-19 in adults
25 October 2021 - If granted marketing authorisation by the European Commission, molnupiravir could be the first oral anti-viral medicine for ...
Posted by Michael Wonder on 25 Oct 2021
The risks of government negotiation of drug prices
25 October 2021 - Under the guise of Medicare ‘negotiations,’ the US House of Representatives is considering a measure that would ...
Posted by Michael Wonder on 25 Oct 2021
Drug pricing reform opponents win most pharma lobbying money
26 October 2021 - Democratic Party law makers holding up proposed drug pricing reforms are among the largest beneficiaries of the ...